Melvin R. Goodes Prize Supports Innovative Projects by Top Researchers While Honoring Pioneering Legacy of Former Warner-Lambert CEO
Carmel Valley's newest winery, Jarman Wines, will introduce two premium varietals to benefit the Alzheimer's Drug Discovery Foundation (ADDF) and to honor the matriarch of the family whose name graces the wines created for her.
Cleveland Clinic Lou Ruvo Center for Brain Health is now recruiting participants for a new, multicenter Alzheimer’s disease (AD) treatment trial, Rasagiline Rescue (R2), which is designed to determine if treatment with rasagiline is associated with improved brain glucose metabolism and improvement in memory.
A mother's voice is the first thing we hear from the time we exit the womb. And its the voice we continue to hear throughout our lives. We model our mother's voice when we first learn to talk. The same voice guides us as we begin to walk. It warns you of potential harm and radiates warmth when you need consolation.
On Monday, April 27, 2015, American theatre director, choreographer, film director and performer Susan Stroman hosted the Alzheimer’s Drug Discovery Foundation’s (ADDF) Ninth Annual Connoisseur’s Dinner at Sotheby’s in New York City. Co-chaired by Leonard A. Lauder of the Estée Lauder cosmetics family, the black-tie event featured fine wine, food and art. More than $2.8 million was raised to support Alzheimer's drug discovery and development
On Wednesday, April 15, 2015, renowned journalist and NPR host Diane Rehm welcomed guests to the Alzheimer’s Drug Discovery Foundation’s (ADDF) Fifth Annual Great Ladies Luncheon & Fashion Show at The Ritz-Carlton in Washington, DC. Rehm, who has long used her public platform to raise awareness for Alzheimer’s disease, spoke eloquently about the need to increase support for drug discovery for Alzheimer’s. She also expressed hope for the future, noting that “there are hundreds of new, potentially disease-modifying drugs in the pipeline.”
Asceneuron SA, an emerging leader in the development of novel, oral small molecule therapeutics targeting tauopathies for Alzheimer’s and related neurodegenerative diseases, today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) awarded it a $325,000 grant to support the development of Asceneuron’s tau modulators.
The Alzheimer’s Drug Discovery Foundation (ADDF) announced today that it has awarded $1 million to GliaCure, a biotechnology company developing innovative therapies based on glial targets, to co-fund a Phase 1b clinical trial in patients with mild to moderate Alzheimer’s disease. The study, which recently began screening volunteers, will determine the safety and tolerability of GliaCure’s primary clinical candidate, GC021109. It follows a 2014 Phase 1a trial which showed GC021109 to be safe and well tolerated in healthy volunteers.
The Alzheimer’s Drug Discovery Foundation (ADDF) is pleased to announce that it is an Official Charity Partner of the 2015 TCS New York City Marathon. The ADDF invites runners who did not secure an individual spot in the 2015 TCS New York City Marathon to join its Runners for Alzheimer’s Research team on Sunday, November 1, 2015.
The Alzheimer’s Drug Discovery Foundation (ADDF) and Pfizer’s Centers for Therapeutic Innovation (CTI) announced today a collaboration designed to advance the development of new small-molecule drugs for Alzheimer’s disease and related dementias. As part of the first-of-its kind collaboration in Alzheimer’s, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer’s drug targets.